Efficacy and Safety of AAV2-REP1 for the Treatment of Choroideremia



Status:Recruiting
Healthy:No
Age Range:18 - Any
Updated:8/10/2018
Start Date:December 11, 2017
End Date:March 31, 2020
Contact:Nightstar Therapeutics
Email:researchenquiries@nightstartx.com
Phone:+44 (0)207 062 2777

Use our guide to learn which trials are right for you!

A Randomised, Open Label, Outcomes-Assessor Masked, Prospective, Parallel Controlled Group, Phase 3 Clinical Trial Of Retinal Gene Therapy For Choroideremia Using An Adeno-Associated Viral Vector (AAV2) Encoding Rab Escort Protein 1 (REP1)

The objective of the study is to evaluate the efficacy and safety of a single sub-retinal
injection of AAV2-REP1 in subjects with Choroideremia.

This is a phase 3 clinical trial of a gene therapy vector made from adeno-associated virus
(AAV) called AAV2-REP1 for the treatment of Choroideremia. Participating subjects will be
required to attend a screening visit during which their suitability for the study will be
assessed, and eligible subjects will be randomized to either AAV2-REP1 treatment or the
control group.

Inclusion Criteria:

- Are willing and able to give informed consent for participation in the study.

- Are male and ≥18 years of age.

- Have a genetically-confirmed diagnosis of CHM.

- Have active disease clinically visible within the macular region in the study eye.

- Fulfill pre-defined visual acuity criteria.

Exclusion Criteria:

- Have a history of amblyopia in the eligible eye.

- Are unwilling to use barrier contraception methods, for a period of 3 months, if
treated with AAV2-REP1.

- Previous intraocular surgery performed in the study eye within 3 months of Visit 1.

- Have any other significant ocular or non-ocular disease/disorder which, in the opinion
of the investigator, may either put the subjects at risk because of participation in
the study, or may influence the results of the study, or the subject's ability to
participate in the study.

- Have participated in another research study involving an investigational product in
the past 12 weeks or received a gene/cell-based therapy at any time previously.
We found this trial at
8
sites
?
mi
from
New York, NY
Click here to add this to my saved trials
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
?
mi
from
Dallas, TX
Click here to add this to my saved trials
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
?
mi
from
Madison, WI
Click here to add this to my saved trials
?
mi
from
Miami, FL
Click here to add this to my saved trials
?
mi
from
Portland, OR
Click here to add this to my saved trials
?
mi
from
Quebec,
Click here to add this to my saved trials